Which develops the global network of trusted medical products regulators

The World Health Organization (WHO) has officially appointed Health Canada. Moreover, the Ministry of Health, Labor and Well-Being / Pharmaceuticals and the Medical Devices Agency (MHLW / PMDA) and the Medicines and Health Products Regulatory Agency (MHRA) of the United Kingdom as international WHO (WLAS), high international regulatory standards for medical products.

With these latest designations. However, which expands the growing list of WLAS, now involving 39 agencies around the world, supporting faster and wider access to medical products provided by quality, especially in low and average income countries (LMIC).

In addition. Meanwhile, the Ministry of the Republic of Korea for Food Safety and Drugs (MFD) – one of the first regulatory authorities to complete WLA assessment for medicines and vaccines in October 2023 – has managed to extend its listing, now which develops global network trusted covering all regulatory functions.

This recognition reflects the deep commitment of these authorities to regulatory excellence. For example, Their designation as a authorities listed by the WHO does not only testify to their robust regulatory systems. For example, but also a critical contribution to global public health. Nevertheless, Solid. Consequently, reliable regulators help ensure that people around the world have access to safe, efficient and high quality medical products. However, “”

Dr Tedros Adhanom Ghebreyesus, Managing Director

About 70% of countries around the world are still faced with significant challenges due to low or inadequate regulatory systems to assess and authorize medical products. The WLA framework promotes regulatory convergence. harmonization and international collaboration, allowing pre-regulatory authorities and regulatory authorities, in particular those of LMIs, to rely on the work of trust and the decisions of the designated agencies. This collaboration supports effective use of which develops global network trusted limited resources. allowing better and faster access to medical products that vital life for millions of additional people.

“The principle of dependence is at the heart of the WHO’s approach to strengthening regulatory systems. a cornerstone for effective, efficient and intelligent regulatory monitoring of medical products,” said Dr. Yukiko Nakatani, Deputy Director General for Health Systems, Access and Data. “The authorities listed by the WHO are key catalysts to promote confidence. transparency and faster access to medical products provided by quality, especially in low and intermediate income countries. »»

In a world where health threats. including lower and falsified medical products, do not know borders, AMS also serve critical preparation and equity pillars, making vital products available more widely, quickly and effectively.

The designations follow a rigorous performance evaluation process carried out by the WHO using its comparative analysis. overall recognized assessment tools. These evaluations were examined by Group Technical which develops global network trusted Advisory on Wlas (Tag-Wla), which met in June 2025.

Canada, Japan and the United Kingdom regulatory authorities were previously recognized as strict regulatory authorities (ARS). Their designation within the framework of WLA marks an important step to go beyond the old SRA system. while ensuring the continuity and stability of global processes for the supply of medical products provided by quality.

Launched in 2022 to replace the previous SRA model. the WLA initiative provides a transparent path based on evidence for global recognition of regulatory authorities to facilitate regulatory convergence and dependence. It is based on decades of leadership to help countries work together more closely on the regulation of medical products. accelerating access to safe, efficient and quality medical products for people around the world.